Financials Hologic, Inc.

Equities

HOLX

US4364401012

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 09:33:07 2024-05-17 am EDT			5-day change	1st Jan Change
74.76 ^USD	-0.25%		-1.06%	+4.90%

May. 09	Argus Adjusts Price Target on Hologic to $95 From $89	MT
May. 06	Lumos Diagnostics Concludes Initial Phase of Development Deal with Hologic for Fetal Fibronectin Test; Shares Jump 6%	MT

Valuation

Fiscal Period: September	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	13,496	17,215	18,710	16,108	16,999	17,492	-	-
Enterprise Value (EV) ¹	15,949	19,553	20,565	16,592	17,095	17,707	16,628	15,376
P/E ratio	-337 x	15.8 x	10.2 x	12.6 x	37.9 x	22.2 x	20.4 x	18.3 x
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	4.01 x	4.56 x	3.32 x	3.31 x	4.22 x	4.34 x	4.12 x	3.88 x
EV / Revenue	4.74 x	5.18 x	3.65 x	3.41 x	4.24 x	4.39 x	3.92 x	3.41 x
EV / EBITDA	14.9 x	12.6 x	6.96 x	7.89 x	13.1 x	13.4 x	11.7 x	10.1 x
EV / FCF	26.9 x	26.4 x	9.21 x	8.07 x	17.8 x	19.2 x	15.8 x	13.5 x
FCF Yield	3.71%	3.79%	10.9%	12.4%	5.61%	5.22%	6.34%	7.4%
Price to Book	6 x	6.32 x	4.44 x	3.36 x	3.44 x	3.62 x	3.14 x	2.84 x
Nbr of stocks (in thousands)	267,306	258,985	253,487	249,653	244,942	233,377	-	-
Reference price ²	50.49	66.47	73.81	64.52	69.40	74.95	74.95	74.95
Announcement Date	11/6/19	11/4/20	11/1/21	10/31/22	11/9/23	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Settembre	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	3,367	3,776	5,632	4,863	4,030	4,032	4,247	4,506
EBITDA ¹	1,069	1,558	2,956	2,104	1,307	1,325	1,427	1,521
EBIT ¹	972.2	1,467	2,866	1,998	1,207	1,231	1,330	1,431
Operating Margin	28.87%	38.84%	50.88%	41.08%	29.95%	30.54%	31.32%	31.75%
Earnings before Tax (EBT) ¹	-95.3	1,002	2,361	1,588	676.1	898.2	1,072	1,197
Net income ¹	-40.2	1,115	1,872	1,302	456	805.3	866.1	949
Net margin	-1.19%	29.53%	33.23%	26.77%	11.31%	19.97%	20.39%	21.06%
EPS ²	-0.1500	4.210	7.210	5.130	1.830	3.377	3.681	4.095
Free Cash Flow ¹	592.5	740.2	2,234	2,055	959.4	924.2	1,054	1,137
FCF margin	17.6%	19.6%	39.66%	42.26%	23.8%	22.92%	24.82%	25.24%
FCF Conversion (EBITDA)	55.43%	47.52%	75.55%	97.69%	73.43%	69.75%	73.88%	74.79%
FCF Conversion (Net income)	-	66.37%	119.35%	157.84%	210.39%	114.76%	121.73%	119.85%
Dividend per Share ²	-	-	-	-	-	-	-	-
Announcement Date	11/6/19	11/4/20	11/1/21	10/31/22	11/9/23	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3
Net sales ¹	1,471	1,436	1,003	953.3	1,074	1,026	984.4	945.3	1,013	1,018	1,000	1,001	1,059	1,059	1,063
EBITDA ¹	752.3	703.6	348.3	299.5	361	345.4	311.9	288.3	315	335.6	334.2	344.4	348.4	357.7	355.7
EBIT ¹	727.3	680.7	323.8	265.7	334.1	320.9	284.5	267.7	288.5	309.9	309.6	319.7	325.2	334.6	332.7
Operating Margin	49.44%	47.41%	32.29%	27.87%	31.1%	31.26%	28.9%	28.32%	28.48%	30.45%	30.95%	31.94%	30.7%	31.59%	31.31%
Earnings before Tax (EBT) ¹	621.9	574.4	248.4	143.4	239.1	279.3	12.1	145.6	191.3	211.5	251.6	258	268.3	281.3	278.6
Net income ¹	499.2	455.7	228.4	118.7	187.4	218.5	-40.5	90.6	246.5	169.9	202.3	206.4	220.6	230.8	228.3
Net margin	33.93%	31.74%	22.78%	12.45%	17.45%	21.29%	-4.11%	9.58%	24.33%	16.69%	20.22%	20.62%	20.82%	21.79%	21.48%
EPS ²	1.950	1.800	0.9000	0.4700	0.7500	0.8700	-0.1600	0.3700	1.030	0.7200	0.8589	0.8774	0.9360	0.9847	0.9758
Dividend per Share ²	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Announcement Date	2/2/22	4/27/22	7/27/22	10/31/22	2/1/23	5/1/23	7/31/23	11/9/23	2/1/24	5/2/24	-	-	-	-	-

¹USD in Million²USD

Estimates

Balance Sheet Analysis

Fiscal Period: September	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	2,453	2,338	1,855	484	95.7	216	-	-
Net Cash position ¹	-	-	-	-	-	-	863	2,115
Leverage (Debt/EBITDA)	2.295 x	1.501 x	0.6274 x	0.23 x	0.0732 x	0.1629 x	-	-
Free Cash Flow ¹	593	740	2,234	2,055	959	924	1,054	1,137
ROE (net income / shareholders' equity)	28%	46.3%	54.1%	33.6%	19.9%	19.3%	18.7%	18.2%
ROA (Net income/ Total Assets)	9.53%	16.4%	23.2%	14.5%	10.8%	9.12%	9.46%	7.6%
Assets ¹	-422	6,819	8,056	8,996	4,219	8,835	9,157	12,486
Book Value Per Share ²	8.410	10.50	16.60	19.20	20.20	20.70	23.90	26.40
Cash Flow per Share ²	2.410	3.390	8.970	8.370	4.220	4.520	5.770	5.500
Capex ¹	57	98.3	96.8	70.6	91.8	90.7	92.4	98.8
Capex / Sales	1.69%	2.6%	1.72%	1.45%	2.28%	2.25%	2.17%	2.19%
Announcement Date	11/6/19	11/4/20	11/1/21	10/31/22	11/9/23	-	-	-

¹USD in Million²USD

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hologic, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

74.95 USD

Average target price

85 USD

Spread / Average Target

+13.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
HOLOGIC, INC.	+4.90%	17.49B
THERMO FISHER SCIENTIFIC	+12.50%	228B
DANAHER CORPORATION	+14.52%	196B
INTUITIVE SURGICAL, INC.	+17.51%	141B
BOSTON SCIENTIFIC CORPORATION	+28.96%	110B
SIEMENS HEALTHINEERS AG	+2.21%	65.88B
EDWARDS LIFESCIENCES CORPORATION	+18.16%	54.3B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+7.63%	52.39B
AGILENT TECHNOLOGIES, INC.	+10.95%	45.22B
GE HEALTHCARE TECHNOLOGIES INC.	+5.10%	37.12B

Other Advanced Medical Equipment & Technology